UCB, Inc. v. Catalent Pharma Solutions, Inc.
By EsqSocial Corporation 30/07/21
Case Name: UCB, Inc. v. Catalent Pharma Solutions, Inc., No. 5:21-cv-00038-GFVT, 2021 WL 1910079 (E.D. Ky. May 12, 2021) (Van Tatenhove, J.) - Drug Product and Patent(s)-in-Suit: Vimpat® (lacosamide); U.S. Patent No. RE38,551 (“the ’551 patent”) - Nature of the Case and Issue(s) Presented: The ’551 patent issued on July 6, 2004, and claimed “anticonvulsant enantiomeric amino acid derivatives,” including lacosamide. UCB held the NDA for Vimpat. Catalent, a contract manufacturer, imported 479 kgs...
By: Robins Kaplan LLP